Cue Biopharma stock (US22966J1060): Analysts set $4 average price target

Cue Biopharma shares trade at $0.70 with analysts forecasting an average price target of $4.00, implying over 470% upside, based on recent reports from three firms.

Cue Biopharma, Inc. shares are trading at $0.70 USD on Nasdaq as of July 3, 2025, according to Zacks as of Jul 3, 2025. Three analysts have set an average short-term price target of $4.00, ranging from $2.00 to $6.00, representing potential upside of 471.43% from the last close.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Cue Biopharma, Inc.
• Sector/industry: Medical - Biomedical and Genetics
• Headquarters/country: United States
• Core markets: United States
• Home exchange/listing venue: Nasdaq (CUE)
• Trading currency: USD

Cue Biopharma: core business model

Cue Biopharma develops novel biologic therapies targeting immune responses for cancer and autoimmune diseases. The company focuses on its Immuno-STAT platform, which reprograms T cells without genetic engineering. This approach aims to deliver antigen-specific immunotherapies directly to target cells. Cue Biopharma is headquartered in the US and listed on Nasdaq under the ticker CUE.

Main revenue and product drivers for Cue Biopharma

Cue Biopharma's pipeline centers on lead candidates like CUE-101 and CUE-102, both in clinical stages for head and neck cancer and other solid tumors. Revenue potential stems from partnerships and milestone payments, with clinical trial progress as key milestones. The company reported development-stage status in recent updates from its investor relations site.

Industry trends and competitive position

The biomedical genetics sector sees growth in immunotherapy, with US market exposure via Nasdaq listing relevant for American investors. Cue Biopharma competes with firms advancing T-cell therapies amid rising demand for precision oncology treatments.

Conclusion

Cue Biopharma remains in clinical development with analyst price targets signaling potential upside amid biotech volatility. Recent targets average $4.00 versus current levels near $0.70, reflecting optimism in its Immuno-STAT platform. US investors track Nasdaq-listed biotechs for innovation exposure, though clinical risks persist.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.